Yahoo Finance HUTCHMED (China) Full Year 2023 Earnings: EPS: US$0.12 (vs US$0.43 loss in FY 2022)
HUTCHMED (China) (LON:HCM) Full Year 2023 Results
Key Financial Results
Revenue: US$838.0m (up 97% from FY 2022).
Net income: US$100.8m (up from US$360.8m loss in FY 2022).
Profit margin: 12% (up from net loss in FY 2022). The move to profitability was primarily driven by higher revenue.
EPS: US$0.12 (up from US$0.43 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
HUTCHMED (China) Earnings Insights
Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Pharmaceuticals industry in the United Kingdom.
Performance of the British Pharmaceuticals industry.
The company's shares are down 2.3% from a week ago.
Risk Analysis
You still need to take note of risks, for example - HUTCHMED (China) has 2 warning signs (and 1 which shouldn't be ignored) we think you should know about.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
